GLP Watchdog

altRX vs Gala

altRX has an open FDA warning letter dated June 8, 2026. Gala has none. On brand-name semaglutide pen, altRX costs $1,800 less a year at standing rates: $1,149 a month against $1,299 a month at Gala. It is one of three products the two sell at comparable terms.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

altRX / Gala

altRX logo

altRX

8.8/10

Gala logo

Gala

8.5/10

FDA warning letters
None on record
Pharmacy
  • RedRock Pharmacy503A
  • Health Warehousetype not stated
  • Precision Medicinetype not stated
  • and 1 more
None named in our record
Lowest standing price
$89/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit altRX
Visit Gala

Both altRX and Gala are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (altRX 8.8, Gala 8.5). How we are paid

What the record shows

  1. 01

    altRX has an open FDA warning letter dated June 8, 2026. Gala has none.

  2. 02

    altRX names four pharmacies. Gala names no compounding pharmacy in our record.

  3. 03

    On brand-name semaglutide pen, altRX costs $1,800 less a year at standing rates: $1,149 a month against $1,299 a month at Gala. It is one of three products the two sell at comparable terms.

  4. 04

    Only altRX lists a price for brand-name tirzepatide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

altRX

Gala

Compounded semaglutide injection

$89/moLower

$1,068 a year

$179/mo

$2,148 a year

Compounded tirzepatide injection

$149/moLower

$1,788 a year

$179/mo

$2,148 a year

Brand-name semaglutide pen

$1,149/moLower

$13,788 a year

$1,299/mo

$15,588 a year

Brand-name tirzepatide pen

$1,249/mo

$14,988 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly plan; multi-month plans are prepaid and non-refundable
Yearly plan for the $179 rate; 72 hours' notice before the billing date to cancel
Refunds
All payments are final and non-refundable, except a partial refund if you are medically disqualified
No refund on cancellation; full refund only if the medical provider disqualifies you

Read off each seller’s own pages. altRX: September 28, 2026. Gala: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for altRX

8.8/10
  • $1,080 a year less on compounded semaglutide injection
  • $360 a year less on compounded tirzepatide injection
  • Sells brand-name tirzepatide pen, which Gala does not price
  • Names its compounding pharmacy
  • Open FDA warning letter, June 8, 2026
Visit altRX

The case for Gala

8.5/10
  • No FDA warning letter on record
  • Names no compounding pharmacy
Visit Gala

Scores

altRX 8.8 · Gala 8.5 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
7.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
7.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

altRX vs Gala: questions

altRX has an open FDA warning letter dated June 8, 2026. Gala has none. Letters are matched to a seller by company, domain and address, never by a similar name.
altRX names four pharmacies. Gala names no compounding pharmacy in our record. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
altRX, by $1,080 a year at standing rates. altRX: $89 a month, about $1,068 a year. Gala: $179 a month, about $2,148 a year.
altRX states you can cancel at any time; refunds: all payments are final and non-refundable, except a partial refund if you are medically disqualified. Gala states you can cancel at any time; refunds: no refund on cancellation; full refund only if the medical provider disqualifies you.
Both altRX and Gala are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (altRX 8.8, Gala 8.5).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks